Use of alprostadil for the treatment of pulmonary hypertension in rats: variations in histopathology and vessel structure

doi:10.3969/j.issn.2095-4344.2015.40.011

Abstract

Abstract:

BACKGROUND: Pulmonary hypertension still lacks effective treatment measures. The effects of alprostadil in the treatment of pulmonary hypertension remain controversial.

OBJECTIVE: To observe the effect of alprostadil in the treatment of pulmonary hypertension induced by chronic hypoxia.

METHODS: 24 experimental rats were randomly and evenly divided into control group, model group, and treatment group. The rats of model and treatment groups were fed in the hypoxic box to establish the animal model of pulmonary hypertension, and the rats of control group were fed in the normal air. After pulmonary hypertension induction, rats from the treatment group were intraperitoneally administered alprostadil injection (5 μg/kg per day) for 4 consecutive weeks.

RESULTS AND CONCLUSION: Compared with the model group, the mean pulmonary artery pressure, right ventricular systolic pressure, pulmonary vascular thickness, size of blood vessels and alveolar wall thickness of rats in the treatment group were obviously decreased. The results suggest that alprostadil can decrease pulmonary artery pressure and prevent lung injury.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

Key words: Alprostadil;, Pulmonary Hypertension, Pulmonary Medicine, Pulmonary Heart Disease

CLC Number:

R318

He Jun-feng, Gu Guo-mei, Yang Le-mei. Use of alprostadil for the treatment of pulmonary hypertension in rats: variations in histopathology and vessel structure [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(40): 6455-6459.

Figures/Tables 2

References

[1] Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122(12): 4306-4313.
[2] Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 2010;28(2):201-212.
[3] Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001;92(1):1-20.
[4] Leng S, He J, Fan W, et al. Bone mesenchymal stem cells for gene transfer of NGF to the adult rat brain: rescue the NGFR p75 positive neurons from fimbria-fornix lesion-induced degeneration. Neurosci Lett. 2008;448(3):282-287.
[5] Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population- based survey. Am J Respir Crit Care Med. 2007;176(8):753- 760.
[6] 李勇,唐捷.前列地尔的药理研究进展[J].西南军医,2006,8(6): 79-81.
[7] 章敬玉,罗勇.前列地尔对慢性肺源性心脏病肺动脉高压疗效的临床研究[J].临床肺科杂志,2014,19(8):1383-1385.
[8] 赵丽娜.前列地尔对特发性间质性纤维化并发肺心病患者临床疗效及生命质量观察[J].中国医药导刊,2013,15(12): 2078- 2079.
[9] 彭公永,胡国平,周玉民,等.常压慢性持续缺氧大鼠肺动脉高压模型的建立[J].广东医学,2011,32(5):573-574.
[10] 邱海艳,何海艳,马航,等.阿托伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的临床研究[J].国际呼吸杂志,2013,33(11): 19-824.
[11] 王素美,吴志峰,刘艳萍.前列腺素E1对肺源性心脏病心力衰竭患者临床疗效的观察[J].临床肺科杂志,2008,13(3):743.
[12] 杨芳,杜庶芳,谢平.前列地尔对慢性阻塞性肺疾病急性加重期的疗效研究[J].国际医药卫生导报,2014,20(18):2840-2843.
[13] Löckinger A, Schütte H, Walmrath D, et al. Protection against gas exchange abnormalities by pre-aerosolized PGE1, iloprost and nitroprusside in lung ischemia-reperfusion. Transplantation. 2001;71(2):185-193.
[14] de Perrot M, Fischer S, Liu M, et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines. Transplantation. 2001; 72(9):1505-1512.
[15] Hybertson BM, Lee YM, Repine JE. Phagocytes and acute lung injury: dual roles for interleukin-1. Ann N Y Acad Sci. 1997;832:266-273.
[16] Grant MM, Burnett CM, Fein AM. Effect of prostaglandin E1 infusion on leukocyte traffic and fibrosis in acute lung injury induced by bleomycin in hamsters. Crit Care Med. 1991; 19(2):211-217.
[17] Kawamura T, Nara N, Kadosaki M, et al. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit Care Med. 2000;28(7):2201-2208.
[18] Kozek-Langenecker SA, Wanzel O, Berger R, et al. Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1. Anesth Analg. 1998;87(5):985-988.
[19] Haché M, Denault A, Bélisle S, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg. 2003;125(3):642-649.
[20] Fortier S, DeMaria RG, Lamarche Y, et al. Inhaled prostacyclin reduces cardiopulmonary bypass-induced pulmonary endothelial dysfunction via increased cyclic adenosine monophosphate levels. J Thorac Cardiovasc Surg. 2004;128(1):109-116.
[21] Yamanaka K, Saluja AK, Brown GE, et al. Protective effects of prostaglandin E1 on acute lung injury of caerulein-induced acute pancreatitis in rats. Am J Physiol. 1997;272(1 Pt 1): G23-30.
[22] Dervin G, Calvin JE Jr. Role of prostaglandin E1 in reducing pulmonary vascular resistance in an experimental model of acute lung injury. Crit Care Med. 1990;18(10):1129-1133.
[23] Leeman M, Vincent JL. Pharmacologic strategies in acute respiratory distress syndrome. Curr Opin Anaesthesiol. 1998; 11(2):123-128.
[24] Adhikari N, Burns KE, Meade MO. Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: systematic review and meta-analysis. Treat Respir Med. 2004; 3(5):307-328.
[25] Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2004;(4):CD004477.
[26] Tang BM, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009; 37(5):1594-1603.
[27] Galvin IM, Steel A, Pinto R, et al. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013;7:CD003707.
[28] Afshari A. Evidence based evaluation of immuno-coagulatory interventions in critical care. Dan Med Bull. 2011;58(9):B4316.
[29] Afshari A, Brok J, Møller AM, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev. 2010;(7):CD002787.
[30] Deal EN, Hollands JM, Schramm GE, et al. Role of corticosteroids in the management of acute respiratory distress syndrome. Clin Ther. 2008;30(5):787-799.
[31] Afshari A, Brok J, Møller AM, et al. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2010;(8): CD007733.
[32] Sud S, Sud M, Friedrich JO, et al. High-frequency ventilation versus conventional ventilation for treatment of acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013;2:CD004085.
[33] Eaton S, Martin G. Clinical developments for treating ARDS. Expert Opin Investig Drugs. 2002;11(1):37-48.
[34] Bund M, Henzler D, Walz R, et al. Cardiopulmonary effects of intravenous prostaglandin E1 during experimental one-lung ventilation. Thorac Cardiovasc Surg. 2006;54(5):341-347.
[35] Hatori N, Takeshima S, Aoki T, Effectiveness of prostaglandin E1 on pulmonary hypertension and right cardiac function induced by single-lung ventilation and hypoventilation. Ann Thorac Cardiovasc Surg. 2000;6(4):236-241.
[36] Tritapepe L, Voci P, Cogliati AA, et al. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med. 1999;27(10):2180-2183.
[37] Hüter L, Schwarzkopf K, Preussler NP, et al. Effects of arginine vasopressin on oxygenation and haemodynamics during one-lung ventilation in an animal model. Anaesth Intensive Care. 2008;36(2):162-166.
[38] Leather HA, Ver Eycken K, Segers P, et al. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med. 2003;31(9):2339-2343.
[39] Bund M, Winterhalter M, Weilbach C, et al. Are there pulmonary vascular or respiratory effects of prostaglandin vehicles (ethanol, glycine buffer) after intravenous infusion or inhalation? Pneumologie. 2007;61(11):721-724.
[40] Gao C, Zhang G, Sun X, et al. The effects of intravenous hyperoxygenated solution infusion on systemic oxygenation and intrapulmonary shunt during one-lung ventilation in pigs. J Surg Res. 2010;159(2):653-659.
[41] Bund M, Henzler D, Walz R, et al. Aerosolized and intravenous prostacyclin during one-lung ventilation. Hemodynamic and pulmonary effects. Anaesthesist. 2004; 53(7):612-620.
[42] Spalding MB, Ala-Kokko TI, Kiviluoma K, et al. The hemodynamic effects of adenosine infusion after experimental right heart infarct in young swine. J Cardiovasc Pharmacol. 2000;35(1):93-99.
[43] Stuesse DC, Giraud GD, Vlessis AA, et al. Hemodynamic effects of S-nitrosocysteine, an intravenous regional vasodilator. J Thorac Cardiovasc Surg. 2001;122(2):371-377.
[44] Della Rocca G, Coccia C, Pompei L, et al. Inhaled aerosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol. 2008;74(11):627-633.
[45] Malliotakis P, Xenikakis T, Linardakis M, et al. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol. 2007;48(2):80-88.
[46] Sidi A, Naik B, Urdaneta F, et al. Treatment of ethanol-induced acute pulmonary hypertension and right ventricular dysfunction in pigs, by sildenafil analogue (UK343-664) or nitroglycerin. Ann Card Anaesth. 2008;11(2): 97-104.
[47] Hedelin P, Kylhammar D, Rådegran G. Dual endothelin receptor blockade with tezosentan markedly attenuates hypoxia-induced pulmonary vasoconstriction in a porcine model. Acta Physiol (Oxf). 2012;204(3):419-434.
[48] Chapman ME, Wideman RF Jr. Hemodynamic responses of broiler pulmonary vasculature to intravenously infused serotonin. Poult Sci. 2002;81(2):231-238.